AtriCure, Inc. (ATRC)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$51.52-1.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · ATRC
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $52 ATRC trades at 4.4× p/s — 1.5× the 3.0× p/s peer median, and above its own 3× history. The market is re-rating it beyond its own range; our $32 fair value is low-confidence here. Analysts target $50–$64. Note: our $32 fair value sits below the entire analyst range ($50–$64). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $55.00 | — | — | Analyst | medium |
| Peer P/FCF | 12M | $27.74 | 26.4 | 1.05 | TTM | medium |
| Peer P/E | 12M | $5.43 | 23.4 | 0.23 | TTM | medium |
| Peer P/S | 12M | $35.28 | 3.0 | 11.66 | TTM | medium |
| PEG | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$50.00 – $64.00 (median $55.00) · 5 analysts · as of 2026-09-02
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $8.62 |
| 37.1 |
| 0.23 |
| TTM |
| medium |
| triangulated | 12M | $6.17 | 23.4 | 0.26 | Triangulated | medium |
| Peer P/E | 3Y | $8.26 | 23.4 | 0.35 | Analyst | medium |
| Peer P/S | 3Y | $46.78 | 3.0 | 15.46 | guidance | medium |
| PEG | 3Y | $13.11 | 37.1 | 0.35 | Analyst | medium |
| Peer P/E | 5Y | $10.92 | 23.4 | 0.47 | Analyst | medium |
| Peer P/S | 5Y | $52.78 | 3.0 | 17.44 | guidance | medium |
| PEG | 5Y | $17.34 | 37.1 | 0.47 | Analyst | medium |